HTLF Bank Sells 1,376 Shares of Johnson & Johnson (NYSE:JNJ)

HTLF Bank lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.6% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 51,837 shares of the company’s stock after selling 1,376 shares during the period. Johnson & Johnson accounts for 0.8% of HTLF Bank’s portfolio, making the stock its 29th largest position. HTLF Bank’s holdings in Johnson & Johnson were worth $7,497,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in JNJ. IFS Advisors LLC increased its stake in Johnson & Johnson by 138.9% in the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock valued at $25,000 after purchasing an additional 100 shares in the last quarter. Highline Wealth Partners LLC acquired a new position in shares of Johnson & Johnson in the 3rd quarter valued at $31,000. Bay Harbor Wealth Management LLC acquired a new stake in Johnson & Johnson during the 4th quarter worth $32,000. RPg Family Wealth Advisory LLC bought a new position in Johnson & Johnson during the third quarter worth about $35,000. Finally, Mowery & Schoenfeld Wealth Management LLC grew its stake in Johnson & Johnson by 58.7% in the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock valued at $40,000 after acquiring an additional 91 shares during the period. Institutional investors own 69.55% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on JNJ shares. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 25th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a report on Wednesday, October 16th. Royal Bank of Canada restated an “outperform” rating and set a $181.00 price objective on shares of Johnson & Johnson in a report on Thursday, January 23rd. Bank of America reduced their target price on shares of Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a research note on Thursday, January 23rd. Finally, Leerink Partners dropped their price target on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $170.67.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $155.23 on Thursday. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The firm has a fifty day simple moving average of $147.48 and a 200 day simple moving average of $156.01. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $168.85. The stock has a market capitalization of $373.73 billion, a PE ratio of 23.34, a P/E/G ratio of 2.46 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The company had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. During the same period in the previous year, the business earned $2.29 EPS. Johnson & Johnson’s revenue for the quarter was up 5.3% compared to the same quarter last year. On average, research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.20%. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Insider Buying and Selling

In related news, Director Mark A. Weinberger acquired 1,000 shares of Johnson & Johnson stock in a transaction on Thursday, December 12th. The stock was purchased at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the transaction, the director now directly owns 1,000 shares in the company, valued at $147,220. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.16% of the stock is owned by insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.